Cargando…
Working together for the family: determination of HER oncogene co-amplifications in breast cancer
HER2 is a well-studied tyrosine kinase (TK) membrane receptor which functions as a therapeutic target in invasive ductal breast carcinomas (IDC). The standard of care for the treatment of HER2-positive breast is the antibody trastuzumab. Despite specific treatment unfortunately, 20% of primary and 7...
Autores principales: | Laurito, Sergio, Branham, María Teresita, Campoy, Emanuel, Real, Sebastián, Cueto, Juan, Urrutia, Guillermo, Gago, Francisco, Tello, Olga, Glatstein, Telma, De la Iglesia, Paola, Atanesyan, Lilit, Savola, Suvi, Roqué, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367656/ https://www.ncbi.nlm.nih.gov/pubmed/32733648 http://dx.doi.org/10.18632/oncotarget.27671 |
Ejemplares similares
-
Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
por: Nasif, Daniela, et al.
Publicado: (2018) -
PAX6 Promoter Methylation Correlates with MDA-MB-231 Cell Migration, and Expression of MMP2 and MMP9
por: Urrutia, Guillermo, et al.
Publicado: (2018) -
Asymmetric Cancer Hallmarks in Breast Tumors on Different Sides of the Body
por: Campoy, Emanuel M., et al.
Publicado: (2016) -
Optimal Fixation Conditions and DNA Extraction Methods for MLPA Analysis on FFPE Tissue-Derived DNA
por: Atanesyan, Lilit, et al.
Publicado: (2017) -
Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation‐dependent probe amplification
por: Yoshikawa, Yoshie, et al.
Publicado: (2021)